what is a glp-1 agonist Non-insulin injectable antidiabetic drugs - agonists and amylinomimetics New GLP-1 Guidelines for Type
Description
The product type segment includes semaglutide, liraglutide, exenatide, dulaglutide, and others, with semaglutide leading the market in 2024, accounting for 58.4% of total share
Hypoglycemia: Especially when combined with other diabetes medications, leading to dangerously low blood sugar levels
This lipid-lowering drug, in addition to lipid control, is used as an adjunct therapy for reducing plasma glucose levels in T2D [183]
Adv Drug Delivery Rev
According to a 2023 study, about 1% of Ozempic users and 0.7% of Saxenda users developed stomach paralysis, compared to 0.3% of those taking Contrave
They all had a high HbA1c level ranging between 7.5% and 10.5% and had a BMI of 25 kg/m^2 or higher
